Correction: Finasteride Modifies the Relation between Serum C–Peptide and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
In this article (Cancer Prev Res 2010 3:279-289), which was published in the March 2010 issue of Cancer Prevention Research (1), Table 4 included a mistake in the calculation of some of the odds ratios. The corrected table appears below:
Table 4. Adiposity/C-peptide interactions in relation to high-grade prostate cancer in the PCPT (placebo arm only).
| C-peptide <3.08 ng/mL | C-peptide >=3.08 ng/mL | ||||
|---|---|---|---|---|---|
| Total n | Cases (n) | OR (95% CI) | Cases (n) | OR (95% CI) | |
| BMI | |||||
| Normal | 49 | 25 | 1.0 (reference) | 24 | 1.43 (0.77-2.66) |
| Overweight | 106 | 41 | 0.80 (0.47-1.36) | 65 | 1.59 (0.96-2.64) |
| Obese | 57 | 19 | 1.62 (0.84-3.15) | 38 | 1.67 (0.95-2.91) |
| Waist Circumference | |||||
| Waist <102 | 92 | 45 | 1.0 (reference) | 47 | 1.50 (0.95-2.38) |
| Waist >=102 | 104 | 34 | 0.98 (0.58-1.66) | 70 | 1.52 (0.93-2.49) |
| Waist:Hip Ratio | |||||
| Waist:Hip <1.0 | 160 | 69 | 1.0 (reference) | 91 | 1.56 (1.09-2.23) |
| Waist:Hip >=1.0 | 36 | 10 | 0.73(0.35-1.49) | 26 | 1.11 (0.65-1.90) |
| Very High Risk | |||||
| Low Risk | 145 | 63 | 1.0 (reference) | 82 | 1.71 (1.19-2.47) |
| High Risk | 46 | 15 | 1.20 (0.57-2.54) | 31 | 1.21 (0.62-2.37) |
References
- Neuhouser ML, Till C, Kristal AR, et al. Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Can Prev Res. 2010;3:279–89. doi: 10.1158/1940-6207.CAPR-09-0188. [DOI] [PMC free article] [PubMed] [Google Scholar]